^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    ColoSTAT®

    Company:
    Vision Tech Bio
    Type:
    CE Marked
    Details
    Evidence

    News

    1year
    Cost-effectiveness of ColoSTAT for primary colorectal cancer screening in the United States. (ASCO 2023)
    CRC screening with ColoSTAT as an alternative to COL could result in multi-billion-dollar cost savings to US private insurers while still detecting most CRC cases and generate population-health gains if used as an alternative to FIT in government-sponsored screening programs.
    HEOR • Cost-effectiveness • Cost effectiveness
    |
    ColoSTAT®
    1year
    A prospective, cross-sectional, multicentre study to evaluate the clinical performance of the ColoSTAT in vitro diagnostic for the detection of biomarkers associated with colorectal cancer. (ASCO 2023)
    The ColoSTAT test met the primary endpoints of performance based on sensitivity and specificity in detecting CRC compared to colonoscopy. ColoSTAT sensitivity and specificity for CRC were comparable with published performance parameters for FIT which range from 74-93% (sensitivity) and 85-96% (specificity).1Clinical trial information: ACTRN12619000301167. Clinical trial information: ACTRN12619000301167.
    Preclinical
    |
    ColoSTAT®